Corcept Therapeutics
Yahoo Finance • 3 months ago
3 US Growth Stocks With Insider Ownership And 20% Revenue Growth
As the U.S. stock market experiences a rally, with major indices like the S&P 500 and Nasdaq climbing due to gains in large-cap technology stocks, investors are keenly observing economic indicators such as interest rate adjustments and oil... Full story
Yahoo Finance • 3 months ago
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here. Despite strong performance from healthcare hol... Full story
Yahoo Finance • 8 months ago
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe en... Full story
Yahoo Finance • 10 months ago
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript February 15, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.28, expectations were $0.25. Corcept Therapeutics Incorpo... Full story
Yahoo Finance • 12 months ago
Corcept Therapeutics Stock Is Down 27%. It’s an ‘Ideal Buying Opportunity.’
A plunge in Corcept Therapeutics shares in response to a disappointing court ruling offers a great chance to buy the shares, according to one analyst team. Last week, a court ruled that Teva Pharmaceutical Industries a maker of generic dru... Full story
Yahoo Finance • last year
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism an... Full story
Yahoo Finance • last year
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, a... Full story
Yahoo Finance • last year
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, a... Full story
Yahoo Finance • last year
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2023. The company will al... Full story
Yahoo Finance • last year
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Could Be 27% Above Their Intrinsic Value Estimate
Key Insights The projected fair value for Corcept Therapeutics is US$17.54 based on 2 Stage Free Cash Flow to Equity Corcept Therapeutics is estimated to be 27% overvalued based on current share price of US$22.25 The US$30.67 analyst pric... Full story
Yahoo Finance • 2 years ago
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial und... Full story
Yahoo Finance • 2 years ago
Q1 2023 Corcept Therapeutics Inc Earnings Call
Participants Atabak Mokari; CFO & Treasurer; Corcept Therapeutics Incorporated Gary Charles Robb; Chief Business Officer & Secretary; Corcept Therapeutics Incorporated Joseph K. Belanoff; Co-Founder, President, CEO & Director; Corcept T... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Announces Preliminary Results of Tender Offer
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic,... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT)... Full story
Yahoo Finance • 2 years ago
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
